



## AGENDA

### WEDNESDAY, JUNE 26, 2024 MORNING SESSIONS

6:30 AM **Breakfast**

#### WELCOME & INTRODUCTIONS

*Vinay Jain*

7:00 AM Welcome & Introductions

*John Heymach/  
Natasha Leighl/Sandip Patel*

#### KEYNOTES

*Natasha Leighl*

7:15 AM Adjuvant and neoadjuvant therapy: Where are we?

*John Heymach*

7:25 AM Should all patients with EGFR+ mNSCLC get combination chemotherapy + EGFR inhibitors?

*Sandip Patel*

7:35 AM Targeting KRAS G12C: Where are we today?

*Ravi Salgia*

7:45 AM SCLC: How much of a game changer is DLL3?

*David Carbone*

7:55 AM **DISCUSSION**

#### SINGLE AGENT EGFR INHIBITOR IN ADJUVANT, NEOADJUVANT AND ADVANCED DISEASE SETTINGS

*Sandip Patel*

8:10 AM Remaining questions about the ADAURA trial: Are all patients benefitting from osimertinib?

*Barbara Melosky*

8:17 AM Osimertinib maintenance post chemoradiotherapy in stage III NSCLC

*Hossein Borghaei*

8:24 AM Efficacy of osimertinib + SABR for treating oligometastatic EGFR+ NSCLC

*Sawsan Rashdan*

8:31 AM Afatinib and furmonertinib in patient with PACC Mutations in EGFR

*John Heymach*

8:38 AM The history and emergence of targeted therapy persister cells (PRC2, EZH2, UTX)

*Patrick Ma*

8:45 AM Single-cell biology of drug-tolerant persister cells in lung cancer

*Hideo Watanabe*

8:52 AM **DISCUSSION**



## AGENDA

### WEDNESDAY, JUNE 26, 2024 MORNING SESSIONS, CONT.

#### TARGETING DLL3

*Anne Chiang*

9:10 AM	Tarlatamab, a DLL3-targeted T-cell engager for R/R SCLC	<i>Hossein Borghaei</i>
9:17 AM	BI 764532, A DLL3 x CD3 T-cell engager	<i>John Heymach</i>
9:24 AM	ZL-1310: A novel DLL3-TOP1 ADC	<i>Robert Brown</i>
9:31 AM	Initial outcomes with a CD3xDLL3xCD137 trispecific T-cell engager in SCLC	<i>Asrar Alahmadi</i>
9:38 AM	Rationale for a DLL3-targeted CAR-T approach to NSCLC and potential advantages over DLL3-targeted BiTEs	<i>Ben Creelan</i>
9:45 AM	1- DLL3-targeted CAR-T therapy in SCLC	<i>Prantesh Jain</i>
9:52 AM	2 - DLL3-targeted CAR-T therapy in SCLC	<i>John Heymach</i>

9:59 AM **DISCUSSION**

10:15 AM **BREAK AND GROUP PHOTO**

#### MONOTHERAPY DATA WITH AGENTS TARGETING KRAS G12C MUTATIONS

*John Heymach*

10:35 AM	Saturability of sotorasib and dose adjustment in KRAS-mutated NSCLC to reduce toxicity	<i>Greg Kalemkerian</i>
10:42 AM	Clinical results with adagrasib in NSCLC	<i>Martin Edelman</i>
10:49 AM	Divarasib – Phase I/II data and ongoing trials	<i>Ben Herzberg</i>
10:56 AM	Olomorasib: a KRAS G12C inhibitor –Single agent data	<i>Marcelo Negrao</i>
11:03 AM	Genetic versus nongenetic mechanisms of resistance to KRAS inhibitors	<i>Ravi Salgia</i>
11:10 AM	Neoadjuvant RAS inhibition in NSCLC	<i>Penelope Bradbury</i>
11:17 AM	<b>DISCUSSION</b>	



## AGENDA

### WEDNESDAY, JUNE 26, 2024 AFTERNOON SESSIONS

#### LUNCH JOHNSON & JOHNSON

#### TARGETING HER2 AND HER3 IN NSCLC *Ravi Salgia*

12:35 PM	Defining clinically relevant HER2 amplifications by preclinical studies in lung cancer to predict response to HER2-targeted therapy	<i>Lynette Sholl</i>
12:42 PM	Trastuzumab deruxtecan in lung cancer Where are we, and where are we going?	<i>Misako Nagasaka</i>
12:49 PM	Spectrum of HER2 alterations in NSCLC and how they correlate as biomarkers for T-DXd	<i>Andreas Saltos</i>
12:56 PM	Zongertinib (BI 1810631), a HER2 TKI in HER2 aberrant solid tumors	<i>John Heymach</i>
1:03 PM	Updates on patritumab deruxtecan, a HER3-targeted ADC in development for NSCLC	<i>Julia Rotow</i>
1:10 PM	Zenocutuzumab: A bispecific in development for NRG1+ fusions	<i>Misako Nagasaka</i>

#### 1:17 PM DISCUSSION

#### ADVANCES IN NEWLY DIAGNOSED SCLC *Wafik El-Deiry*

1:35 PM	What is the role for checkpoint inhibitors in LS-SCLC?	<i>Anne Chiang</i>
1:42 PM	Real-world takeaways from patient-specific data from the Canadian CASCADE trial in SCLC	<i>Paul Wheatley-Price</i>
1:49 PM	IMForte (Role of Maintenance: Atezo + lurbinectedin in ES-SCLC)	<i>Apar Ganti</i>
1:56 PM	Optimal therapeutic approaches to three subtypes of SCLC (subtype A or N, SLFN11+; subtype A or N, SLFN11-; subtype I)	<i>Anne Chiang</i>
2:03 PM	ctDNA methodologies in SCLC and initial outcomes from an IIT with pembrolizumab after chemoradiotherapy and ctDNA-tracked disease dynamics	<i>Wade Iams</i>
2:10 PM	Microenvironment states govern SCLC plasticity: Findings from spatial transcriptomic analyses of rapid autopsy specimens	<i>Parth Desai</i>

#### 2:17 PM DISCUSSION



## AGENDA

### WEDNESDAY, JUNE 26, 2024 AFTERNOON SESSIONS, CONT.

#### NOVEL ANTIBODY DRUG CONJUGATES IN DEVELOPMENT

*Natasha Leigh*

2:35 PM	Telisotuzumab vedotin: Rationale for targeting MET in NSCLC	<i>Barbara Melosky</i>
2:42 PM	Precision testing of ADCs in lung cancer using patient-derived xenografts	<i>David Barbie</i>
2:49 PM	Ifinatamab deruxtecan, an anti-B7-H3 ADC in development for SCLC	<i>Rafael Santana-Davila</i>
2:56 PM	ABBV-706: a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers	<i>Anne Chiang</i>
3:03 PM	Lessons learned from combining berzosertib + sacituzumab in SCLC	<i>Parth Desai</i>

3:10 PM **DISCUSSION**

#### CNS METASTASES

*Martin Edelman*

3:25 PM	Genomic profiling and molecular targeting of lung cancer with brain metastases	<i>Haiying Cheng</i>
3:32 PM	Modern stereotactic radiation therapy approaches for lung cancer brain metastases	<i>Rupesh Kotecha</i>
3:39 PM	How do we treat leptomeningeal progression on osimertinib?	<i>Sawsan Rashdan</i>
3:46 PM	Using the Biocept biomarker test to evaluate circulating tumor cells in the CSF to detect NSCLC leptomeningeal disease	<i>Ramya Muddasani</i>

3:53 PM **DISCUSSION**

6:00 PM **WELCOME DINNER**



## AGENDA

### THURSDAY, JUNE 27, 2024, MORNING SESSIONS

6:30 AM **Breakfast**

#### KEYNOTES *Sandip Patel*

7:00 AM Has radiation replaced surgery for early-stage NSCLC? *Drew Moghanaki*

7:10 AM Adjuvant EGFRi and ALKi: Heading to a cure *Natasha Leighl*

7:20 AM Biology and clinical relevance of STK11 *David Barbie*

7:30 AM **DISCUSSION**

#### ROLE OF PATIENT ADVOCACY IN CLINICAL TRIALS IN NSCLC *Ken Culver and Marcia Horn*

7:40 AM Boosting equity and inclusion in cancer research *Jhanelle Gray*

7:47 AM Clinical trial involvement as an ongoing need in patient advocacy *Paul Wheatley-Price*

7:54 AM Lessons learned from the WIN Consortium's evaluation of individual patients' experiences on emerging therapies *Wafik El-Deiry*

8:01 AM Including phase I studies as part of a multidisciplinary approach to therapy *Nagla Karim*

8:08 AM The guidelines are never enough: Pros and cons of guidelines in NSCLC *Greg Kalemkerian*

8:15 AM **DISCUSSION**

#### NEOADJUVANT APPROACHES *Jhanelle Gray*

8:30 AM Controversies and remaining questions in neoadjuvant treatment of lung cancer *Jhanelle Gray*

8:37 AM Pragmatic and optimal approaches when using checkpoint inhibitors *Deepa Rangachari*

8:44 AM pCR as a primary endpoint for neoadjuvant trials and when it should be avoided *Jamie Chافت*

8:51 AM What is the impact of neoadjuvant chemoimmunotherapy on resectability and outcomes of NSCLC tumors? *Robert Merritt*

8:58 AM Post-neoadjuvant resections: Open questions (edema, drug half-life, etc.) *Erin Gillaspie*

9:05 AM Tools for objective pathologic assessment of response to neoadjuvant therapy with immunotherapy +/- chemotherapy *Ignacio Wistuba*

9:12 AM Current trials of targeted neoadjuvant therapy in NSCLC (ALK, RET, EGFR, NTRK, ROS1, etc.) *Jay Lee*

9:19 AM **DISCUSSION**

9:35 AM **BREAK**



## AGENDA

### THURSDAY, JUNE 27, 2024, MORNING SESSIONS, CONT.

#### RAS INHIBITOR COMBINATIONS

*John Heymach*

9:45 AM	Sotorasib combinations in NSCLC with KRAS G12C mutation	<i>Corey Langer</i>
9:52 AM	Krascendo: Divarasib + pembrolizumab in KRAS G12C NSCLC	<i>Haiying Cheng</i>
9:59 AM	SUNRAY-1: Olomorasib + pembrolizumab versus pembrolizumab in KRAS G12C-mutated NSCLC	<i>Marcelo Negrao</i>
10:06 AM	Next-generation approaches to RAS: G12D, pan-RAS inhibitors and beyond	<i>Joshua Sabari</i>
10:13 AM	RMC-6236: A RAS off-on inhibitor	<i>Ben Herzberg</i>
10:20 AM	Targeting SOS1/SHP2: Where are we?	<i>Trever Bivona</i>

10:27 AM **DISCUSSION**

#### EXON 20 AND RESISTANCE EGFR MUTATIONS

*Jamie Chافت*

10:45 AM	An overview of the biology and treatment landscape of EGFR exon 20 insertion mutations	<i>Julia Rotow</i>
10:52 AM	Phase III results with chemotherapy plus amivantamab in exon 20 +ve NSCLC	<i>Joshua Sabari</i>
10:59 AM	Management of resistance in patients with advanced EGFRmut NSCLC	<i>Deepa Rangachari</i>
11:06 AM	Clinical approaches to second-site mutations in EGFR for NSCLC	<i>Julia Rotow</i>
11:13 AM	Patient Advocacy Perspective	<i>Marcia Horn</i>

11:20 AM **DISCUSSION**

#### TARGETING ALK

*Saiama Waqar*

11:35 AM	Novel learnings from the biology of ALK	<i>Ravi Salgia</i>
11:42 AM	Adjuvant alectinib in surgically resected ALK fusion NSCLC	<i>Patrick Ma</i>
11:49 AM	A look at the 5-year CROWN data for lorlatinib in ALK+ NSCLC	<i>Misako Nagasaka</i>
11:56 AM	Targeted therapy in the neoadjuvant setting for NSCLC, including ALK (NAUTICA)	<i>Jamie Chافت</i>
12:03 PM	Patient Advocacy Perspective	<i>Ken Culver</i>

12:10 PM **DISCUSSION**



## AGENDA

### THURSDAY, JUNE 27, 2024, AFTERNOON SESSIONS

#### WORKING LUNCH SESSION: INDUSTRY PIPELINE PRESENTATIONS

*Vinay Jain*

12:25 PM	Jazz pipeline in lung cancer	<i>Badri Rengarajan</i>
12:35 PM	Johnson & Johnson pipeline in lung cancer	<i>Josh Bauml</i>
12:45 PM	Genentech pipeline in lung cancer	<i>Ilze Bara</i>
12:55 PM	Lilly pipeline in lung cancer	<i>Geoff Oxnard</i>
1:05 PM	Daiichi Sankyo pipeline in lung cancer	<i>Sudar Phani</i>

#### TARGETING RET/RAF/ROS-1/PRMT5

*Misako Nagasaka*

1:20 PM	Selpercatinib and pralsetinib in RET-rearranged lung cancer	<i>Ravi Salgia</i>
1:27 PM	The (un)necessary study in RET inhibition	<i>Corey Langer</i>
1:34 PM	Emerging data for selpercatinib for EGFR-mutated NSCLC with RET-driven resistance to EGFR inhibitors	<i>Julia Rotow</i>
1:41 PM	Optimizing treatment for BRAF mutations in NSCLC based on mutational class	<i>Michael Offin</i>
1:48 PM	A review of the frontline options for BRAF-mutated NSCLC	<i>Marcelo Negrão</i>
1:55 PM	BDTX-4933: A novel pan-RAF inhibitor	<i>Julio Hajdenberg</i>
2:02 PM	Opportunities and challenges in targeting ROS1 in NSCLC	<i>Rajat Thawani</i>
2:09 PM	Rationale for targeting MAT2A and MTA with a combination of IDE397 and AMG 193	<i>Quincy Chu</i>

2:16 PM **DISCUSSION**



## AGENDA

### THURSDAY, JUNE 27, 2024, AFTERNOON SESSIONS, CONT.

#### NOVEL BISPECIFICS, ADC AND RADIATION SENSITIZERS IN HEAD AND NECK CANCER

*Hossein Borghaei*

2:35 PM	Phase I/II data and planned trials with petosemtamab: an EGFR/LGR5 bispecific in HNSCC	<i>Ari Rosenberg</i>
2:42 PM	Altering the HNSCC landscape: Breaking through the tumor defense with EGFR-TGF $\beta$ blockade	<i>David Raben</i>
2:49 PM	A novel VEGFR inhibitor, zanzalintinib + pembrolizumab in head and neck cancer	<i>Robert Haddad</i>
2:56 PM	Xevinapant, a SMAC mimetic, with chemoradiotherapy versus chemoradiotherapy as an adjuvant therapy post resection of HNSCC	<i>Ranee Mehra</i>
3:03 PM	Enfortumab vedotin ADCs targeting Nectin-4, in taxane-naïve HNSCC	<i>Ari Rosenberg</i>
3:10 PM	Tisotumab vedotin in TF-expressing head and neck cancer	<i>Luana G. Sousa</i>
3:17 PM	<b>DISCUSSION</b>	

#### BIOMARKER AND TRANSLATIONAL STUDIES WITH CHECKPOINT INHIBITORS

*John Heymach*

3:35 PM	Circulating single T-cells liquid biopsy cytokine immune profiling as biomarker for immunotherapy	<i>Patrick Ma</i>
3:42 PM	An ex-vivo investigation of the impact of immune cells on tumor biology using a microfluidic chip	<i>Nan Sethakorn</i>
3:49 PM	Clinical data on the impact of gut microbiome on treatment outcomes in lung cancer	<i>Bertrand Routy</i>
3:56 PM	Implementing spatial tools and multiplexing technologies to assess immune response and infiltration	<i>Ignacio Wistuba</i>
4:03 PM	A 25-gene prognostic panel for squamous cell carcinoma response and outcomes	<i>Fawzi Abu Rous</i>
4:10 PM	Targeting the vulnerabilities of TP53 mutations using proteasome-targeted therapies	<i>Eziafa Oduah</i>
4:17 PM	<b>DISCUSSION</b>	





## AGENDA

### FRIDAY, JUNE 28, 2024, MORNING SESSIONS

6:30 AM **Breakfast**

#### KEYNOTES

*John Heymach*

7:00 AM	ctDNA to understand tumor evolution and guide therapy	<i>Max Diehn</i>
7:10 AM	Immunooncology approaches beyond PD-1 in HNSCC (PVRIG, LAG3, TIM3)	<i>Robert Haddad</i>
7:20 AM	Investigating and targeting gene fusions in YAP and other proteins in lung cancer	<i>Trever Bivona</i>
7:30 AM	Recent progress with datopotamab deruxtecan in NSCLC	<i>Joshua Sabari</i>
7:40 AM	Sacituzumab govitecan: Trial update and its potential place in the treatment landscape	<i>Saiama Waqar</i>

7:50 AM **DISCUSSION**

#### CHEMOTHERAPY COMBINATIONS WITH EGFR INHIBITORS IN ADVANCED DISEASE SETTINGS

*Joshua Sabari*

8:05 AM	Vertical and horizontal inhibition of EGFR/MET pathway: Amivantamab plus lazertinib combinations in 1st and 2nd line NSCLC	<i>Corey Langer</i>
8:12 AM	Chemotherapy plus osimertinib in advanced NSCLC	<i>Hossein Borghaei</i>
8:19 AM	Impact of subcutaneous amivantamab plus lazertinib combinations in refractory EGFR-mutated NSCLC	<i>Natasha Leigh</i>
8:26 AM	Phase I/II study of amivantamab-based combinations with MET inhibitors and PD-1	<i>Sandip Patel</i>
8:33 AM	Findings from a comprehensive genomic analysis of MET Exon 14 skipping	<i>So Yeon Kim</i>

8:40 AM **DISCUSSION**



## AGENDA

### FRIDAY, JUNE 28, 2024, MORNING SESSIONS, CONT.

#### CHEMOTHERAPY AND NOVEL TARGETED APPROACHES FOR RELAPSED SCLC

*Sonam Puri*

8:55 AM	Real-world data on lurbinectedin in SCLC	<i>Apar Ganti</i>
9:02 AM	A case-based look at lurbinectedin and how to select the right SCLC patients	<i>Asrar Alahmadi</i>
9:09 AM	Emerging therapeutics including combinations with lurbinectedin in SCLC	<i>Wafik El-Deiry</i>
9:16 AM	BI 764532, A DLL3 x CD3 T-cell engager	<i>Bjoern Rueter</i>
9:23 AM	BMS-986012, an antifucosyl-GM1 mAb as a synergistic therapy with nivolumab in SCLC after failure of carboplatin + etoposide	<i>Neal Ready</i>
9:30 AM	RYZ101: Actinium-225-labeled antibody therapy in ES-SCLC (RayzeBio)	<i>Sonam Puri</i>
9:37 AM	Targeting PARP in SCLC: An update on current data and emerging therapy	<i>Nagla Karim</i>
9:44 AM	Targeting MYC and LSD1 in SCLC	<i>Rafael Santana-Davila</i>

9:51 AM **DISCUSSION**

10:10 AM **BREAK**

#### ADVANCES IN CHEMORADIOOTHERAPY

*Drew Moghanaki*

10:20 AM	Strategies to reduce cardiac toxicities for thoracic tumors	<i>Charles Simone</i>
10:27 AM	Hypoxia-targeted PET scans to determine optimal radiation doses and patterns	<i>Billy Loo</i>
10:34 AM	Synergistic impact of chemotherapy-free radioimmunotherapy for locally advanced NSCLC	<i>Steven Lin</i>
10:41 AM	Papaverine targets mitochondrial electron transport chain, and is potentially synergistic with chemoradiotherapy for NSCLC	<i>Jeremy Brownstein</i>

10:48 AM **DISCUSSION**

#### TARGETING CTLA4, TIGIT, AND LAG-3

*Sandip Patel*

11:05 AM	Using combination PD-1 + CTLA4-targeted therapy to overcome immune resistance in lung cancer	<i>David Carbone</i>
11:12 AM	Update on the trials with tremelimumab plus durvalumab in metastatic NSCLC	<i>Jacob Kaufman</i>
11:19 AM	Trials with anti-TIGIT antibody tiragolumab in NSCLC	<i>Sandip Patel</i>
11:26 AM	Data for efitilagimod alpha (soluble LAG-3) and pembrolizumab in frontline NSCLC	<i>Wade Iams</i>

11:33 AM **DISCUSSION**



## AGENDA

### FRIDAY, JUNE 28, 2024, AFTERNOON SESSIONS

#### WORKING LUNCH SESSION: INDUSTRY PIPELINE PRESENTATIONS

*Vinay Jain*

11:50 AM	Pfizer pipeline in lung cancer	<i>Kirsten Duncan</i>
12:00 PM	Gilead pipeline in lung cancer	<i>Darin Dobler</i>
12:10 PM	Zai Lab pipeline in lung cancer	<i>Rafael Amado</i>
12:20 PM	Merus pipeline in lung/head and neck cancer	<i>David Yao</i>
12:30 PM	Boehringer Ingelheim pipeline in lung cancer	<i>Bjoern Rueter</i>

#### TRIAL DESIGN

*Jhanelle Gray*

12:45 PM	Current progress and future goals for the LungMAP Study (how treatment groups have expanded and how it accommodated immune therapy)	<i>Saiama Waqar</i>
12:52 PM	Lung-MAP S1800A: A trial testing ramucirumab as a potentially synergistic approach with pembrolizumab in NSCLC	<i>Konstantin Dragnev</i>
12:59 PM	Shedding light on the VA precision oncology platform and the importance of data-driven studies over models	<i>Drew Moghanaki</i>
1:06 PM	Novel ways to collect QoL data (includes digital surveys based on 200-participant study)	<i>Claire Mulvey</i>
1:13 PM	Pharma Perspectives on Progressive Trial Design	<i>Geoff Oxnard</i>

1:20 PM **DISCUSSION**

#### SURGICAL ADVANCES

*Timothy Mullett*

1:35 PM	Emerging techniques to employ robotic interventions to biopsy, diagnose, and resect in a single procedure	<i>Robert Merritt</i>
1:42 PM	Salvage resection after definitive chemoradiation therapy	<i>Eric Vallieres</i>
1:49 PM	Optimizing resections: How little resection is too little?	<i>Erin Gillaspie</i>
1:56 PM	<b>DISCUSSION</b>	



## AGENDA

### FRIDAY, JUNE 28, 2024, AFTERNOON SESSIONS, CONT.

#### ADVANCES IN RADIATION TECHNOLOGY

*Max Diehn*

2:10 PM	An overview of technology for SBRT of stage I NSCLC	<i>Rupesh Kotecha</i>
2:17 PM	Postoperative radiation therapy in persistent N2 disease	<i>Jeremy Brownstein</i>
2:24 PM	Proton pencil Beam scanning SBRT	<i>Charles Simone</i>
2:31 PM	PET-directed radiation therapy in NSCLC	<i>Terence Williams</i>
2:38 PM	FLASH radiation therapy to deliver ultra-high dose rate radiation to maintain efficacy while reducing toxicity	<i>Billy Loo</i>
2:45 PM	Biological mechanisms of radiation resistance in NSCLC	<i>Terence Williams</i>

2:52 PM **DISCUSSION**

#### VACCINE AND ONCOLYTIC VIRUS AND CELLULAR THERAPY FOR NSCLC

*Neal Ready*

3:10 PM	Long-term disease control with the Iovance TIL therapy in metastatic NSCLC	<i>David Carbone</i>
3:17 PM	The biology and rationale for using CD40L as a strategy for TIL augmentation in EGFR, ALK, ROS1, or HER2-driven NSCLC	<i>Ben Creelan</i>
3:24 PM	Adjuvant mRNA vaccine therapy + PD-1-targeted checkpoint therapy in NSCLC	<i>Jay Lee</i>
3:31 PM	Neoepitope-targeted dendritic cell vaccines in early-stage NSCLC, including the neoadjuvant setting	<i>Amy Cummings</i>
3:38 PM	Early clinical experience with an intratumoral oncolytic virus, MEM-288, in lung tumors and abscopal effects	<i>Andreas Saltos</i>

3:45 PM **DISCUSSION**

#### STRATEGIES TO ENHANCE CHECKPOINT INHIBITOR THERAPIES

*Barbara Melosky*

4:00 PM	Using alirocumab, an anti-PCSK9 mAb to restore sensitivity to pembrolizumab	<i>Neal Ready</i>
4:07 PM	Novel immune checkpoints in lung cancer, including HHLA2	<i>Haiying Cheng</i>
4:14 PM	Clinical data targeting A2A + radiation + immune checkpoint inhibition in lung cancer	<i>Prantesh Jain</i>

4:21 PM **DISCUSSION**



## AGENDA

### SATURDAY, JUNE 29, 2024, MORNING SESSIONS

6:30 AM **Breakfast**

#### KEYNOTES

*Corey Langer*

7:00 AM Using less therapy to avoid treatment resistance: An evolutionary and ecological view and early clinical evidence *Martin Edelman*

7:10 AM MTAP deletion as a pan-cancer biomarker in the clinical setting *Lynette Sholl*

7:20 AM How can our understanding of the microbiome improve our ability to use checkpoint inhibitors *Bertrand Routy*

7:30 AM Strategies to reduce the cost of thoracic surgery *Eric Vallieres*

7:40 AM **DISCUSSION**

#### ADVANCES IN ctDNA AND TUMOR BIOLOGY

*David Barbie*

7:55 AM Biomarker development and screening techniques for early detection of lung cancer *Edwin Ostrin*

8:02 AM Ultrasensitive MRD detection through PhasED-Seq to predict when resected or irradiated tumors will recur *Max Diehn*

8:09 AM Biology and prognostic implications of circulating giant cells in lung cancer as predictors of metastasis *Steven Lin*

8:16 AM Challenges using ctDNA for adapting therapy: Evidence for augmenting therapy for PD-L1 high patients with detectable ctDNA after 6 weeks on single-agent pembrolizumab *Penelope Bradbury*

8:23 AM Identifying and manipulating lineage markers and transcriptomes in lung cancer and potential clinical impacts *Hideo Watanabe*

8:30 AM ctDNA and liquid biopsy in oligometastatic disease *Nan Sethakorn*

8:37 AM A preclinical investigation the role of mitochondrial mutations in cancer development *Amy Cummings*

8:44 AM **DISCUSSION**



## AGENDA

### SATURDAY, JUNE 29, 2024, MORNING SESSIONS, CONT.

#### SCREENING AND TOBACCO CESSATION

*Eric Vallieres*

9:00 AM	Lung cancer screening: The Kentucky experience (they have become #2 in the country for cancer screening)	<i>Timothy Mullett</i>
9:07 AM	How do we move the needle on screening for NSCLC?	<i>Jhanelle Gray</i>
9:14 AM	Bronchoscopy technologies to recreate CT scans to the bronchial tree and locate the nodules and stage the mediastinum	<i>Edwin Ostrin</i>
9:21 AM	Early detection of lung cancer in a diagnostic setting: An update on improving technology	<i>Max Diehn</i>
9:28 AM	SBRT as novel treatment for severe pulmonary emphysema	<i>Billy Loo</i>
9:35 AM	Rationale for using canakinumab as a method of primary prevention of lung cancer in high-risk patients who qualify for screening	<i>Konstantin Dragnev</i>
9:42 AM	Evaluating the benefits of tobacco cessation at the time of cancer diagnosis	<i>Timothy Mullett</i>

9:49 AM **DISCUSSION**

10:05 AM **BREAK**

#### ADVANCES IN MESOTHELIOMA

*Vinay Jain*

10:15 AM	Translational PDX studies in mesothelioma	<i>Michael Offin</i>
10:22 AM	What's coming next with checkpoint inhibitors in mesothelioma?	<i>Quincy Chu</i>
10:29 AM	Pathologic assessment of treatment response to neoadjuvant therapy in resected pleural mesothelioma	<i>Jennifer Sauter</i>
10:36 AM	NF2-YAP/TAZ IHC as a marker for the detection of NF2 alterations in diffuse pleural mesothelioma	<i>Jennifer Sauter</i>

10:43 AM **DISCUSSION**



## AGENDA

### SATURDAY, JUNE 29, 2024, MORNING SESSIONS, CONT.

#### TRANSLATIONAL BIOLOGY

*Robert Haddad*

11:00 AM	Treatment of nasopharyngeal cancer: A 2024 perspective	<i>Victoria Villaflor</i>
11:07 AM	Novel approaches to salivary gland cancer (B7-H4 inhibitor, sacituzumab govitecan, trastuzumab deruxtecan, etc.)	<i>Luana G. Sousa</i>
11:14 AM	Exploring the connection between epigenetics in HNSCC and socioeconomic status and outcomes	<i>Ranee Mehra</i>
11:21 AM	Oral cavity biomarkers as prognostic factors in head and neck cancer: A retrospective analysis	<i>Victoria Villaflor</i>
11:28 AM	HB200, an HBV-specific antigen encoding the HPV16 E6/E7 antigens with or without pembrolizumab to induce anti-tumor immunity in PD-L1+ head and neck cancer	<i>Ari Rosenberg</i>
11:35 AM	Precision medicine for NET: What's out there?	<i>Claire Mulvey</i>
11:42 AM	TRAF2 as a specific resistance pathway in neuroendocrine tumors	<i>Jacob Kaufman</i>
11:49 AM	<b>DISCUSSION</b>	